This Week in Neurology — Jul 1, 2026

Welcome to This Week in Neurology. This week we're covering 10 notable papers spanning advances in multiple sclerosis management, biomarker and pathologic insights in neurodegenerative diseases, and novel strategies in acute stroke and concussion. Let's dive in.

We begin with a major clinical milestone in multiple sclerosis management. For years, clinicians have utilized anti-CD20 monoclonal antibodies for relapsing multiple sclerosis, but head-to-head trials comparing the most common options have been lacking. This week, The New England Journal of Medicine published the OVERLORD-MS trial, a phase three, multicenter, double-blind, noninferiority trial comparing rituximab directly to ocrelizumab [1]. The investigators randomized two hundred and eighteen adults with newly diagnosed relapsing multiple sclerosis and recent disease activity to receive either rituximab or ocrelizumab every six months for twenty-four months. Looking at the primary endpoint, which was the absence of new or enlarging lesions on T2-weighted magnetic resonance imaging from month six to month twenty-four, the results were highly reassuring. The estimated probability of remaining free of new or enlarging lesions was ninety-two point two percent with rituximab and ninety-four point eight percent with ocrelizumab. This translated to a risk difference of negative two point six percentage points, successfully meeting the prespecified noninferiority criterion. Furthermore, clinical relapse rates, disability outcomes, and cognitive performance profiles appeared to be similar between the two groups. While serious adverse events were comparable, occurring in about seven to eight percent of patients in both arms, infections were notably more common in the rituximab group, affecting eighty-two percent of participants compared to sixty-nine percent in the ocrelizumab group. This trial provides robust evidence that rituximab is a highly effective, noninferior option for early disease control, though clinicians must remain vigilant regarding the slightly higher infection risk.

This finding on B-cell depletion is further supported by a real-world observational study published in the Multiple Sclerosis Journal, which examined the impact of different disease-modifying therapies on chronic lesion tissue expansion [10]. Chronic lesion tissue expansion represents the slow, concentric growth of established multiple sclerosis lesions, a process that is closely linked to central brain atrophy and long-term disability progression. Utilizing clinical data from the MSBase registry and the MSBase Imaging Repository, researchers analyzed over sixteen hundred stable treatment epochs from five hundred and sixty-four patients. After adjusting for demographic, clinical, and imaging covariates, B-cell depleting therapy emerged as the only disease-modifying therapy associated with a significantly lower rate of chronic lesion tissue expansion compared to fingolimod. This suggests that B-cell depletion may target the compartmentalized inflammation responsible for progressive tissue damage, offering a promising therapeutic avenue for slowing down the insidious progression of multiple sclerosis.

However, detecting this progressive disease activity remains a major challenge in clinical practice. A companion study in the Multiple Sclerosis Journal evaluated how often conventional side-by-side magnetic resonance imaging comparisons miss radiologic disease activity [4]. The retrospective cohort study included three hundred and fourteen people with multiple sclerosis who had three consecutive brain scans. The researchers applied semiautomated coregistration-fusion software to fluid-attenuated inversion recovery sequences on scans that had originally been reported as stable using conventional side-by-side visual analysis. Semiautomated coregistration-fusion identified missed new lesions in nearly twenty-one percent of these supposedly stable patients. Crucially, missing these lesions was not clinically benign. Patients with missed radiologic disease activity had a tenfold higher risk of showing future radiologic disease activity on subsequent scans, and more than double the risk of experiencing clinical disease activity, such as a relapse or confirmed disability progression. Each additional missed lesion was associated with a twenty percent increase in the rate of new lesions on future scans. These findings argue strongly for the clinical adoption of coregistration-fusion software, as relying solely on conventional visual comparison can lead to underestimating disease activity and delaying necessary treatment optimization.

Turning our attention to neurodegenerative diseases, we start with a highly promising diagnostic development published in Nature Medicine [3]. Detecting Alzheimer's disease before clinical symptoms manifest is a major priority, especially with the emergence of disease-modifying therapies. Researchers investigated blood-based circular RNAs, which are highly stable, non-coding RNAs that are enriched in the brain and capable of crossing the blood-brain barrier. Analysing blood data from over twelve hundred individuals, the team identified thirty-four circular RNAs associated with Alzheimer's disease status. A predictive model utilizing these thirty-four circular RNAs classified biomarker-confirmed Alzheimer's disease with an area under the curve of zero point nine four five, outperforming plasma phosphorylated tau-two-one-seven, which achieved an area under the curve of zero point eight seven seven. When the circular RNA panel was integrated with plasma p-tau-two-one-seven, the diagnostic accuracy reached an exceptional area under the curve of zero point nine seven seven. Additionally, the circular RNA model demonstrated high specificity for Alzheimer's disease, showing low predictive power for Parkinson's disease, frontotemporal dementia, and other neurodegenerative conditions. It also outperformed both p-tau-two-one-seven and amyloid positron emission tomography in predicting progression to symptomatic Alzheimer's disease in cognitively unimpaired cohorts, suggesting that these blood-based circular RNAs could serve as highly precise biomarkers for early diagnosis and clinical trial stratification.

The clinical picture of neurodegeneration is often complicated by the coexistence of multiple pathologies, particularly Alzheimer's disease and alpha-synuclein pathology. A study in Neurology characterized the neuropsychological profiles and longitudinal cognitive trajectories of three hundred and forty-nine patients from a memory clinic cohort with biomarker-confirmed diagnoses [8]. The cohort was divided into those with Alzheimer's disease alone, Alzheimer's with alpha-synuclein pathology, dementia with Lewy bodies alone, and dementia with Lewy bodies with Alzheimer's pathology. At baseline, the investigators found distinct cognitive signatures. Compared to patients with isolated Alzheimer's disease, those with mixed Alzheimer's and alpha-synuclein pathology performed significantly worse on tests of visual attention, processing speed, and ideomotor apraxia. Conversely, patients with primary dementia with Lewy bodies who also had Alzheimer's pathology showed greater impairment in visual memory, constructional praxis, and executive function than those with isolated dementia with Lewy bodies. Longitudinally, patients with a primary Alzheimer's diagnosis and mixed pathology exhibited a much steeper decline in memory, language, and visuospatial function over time. These findings emphasize that identifying mixed pathology in vivo using biomarkers is critical for establishing an accurate prognosis and designing clinical trials.

This theme of overlapping pathologies extending to other neurodegenerative conditions is further illustrated by a study in Movement Disorders, which investigated the prognostic impact of Alzheimer's disease cerebrospinal fluid biomarkers in patients with progressive supranuclear palsy [6]. In a cohort of eighty-five newly diagnosed progressive supranuclear palsy patients, researchers evaluated the amyloid-beta-forty-two, total tau, and phosphorylated tau levels. They found that an Alzheimer's disease-positive profile, defined by a phosphorylated tau to amyloid-beta-forty-two ratio of zero point zero eight or greater, was present in nearly nineteen percent of the patients. While this biological subgroup did not differ from other progressive supranuclear palsy patients in terms of baseline clinical phenotype or disease severity, the presence of the Alzheimer's signature was a powerful independent predictor of mortality. Patients with the Alzheimer's-positive profile had markedly shorter survival times, highlighting this ratio as a pragmatic prognostic tool for patient stratification and counseling.

To understand how these pathologic processes translate into clinical complications, a retrospective study in Neurology examined the neuropathologic substrates of clinically active seizures in a large autopsy-confirmed cohort of over thirty-four hundred patients with Alzheimer's disease or dementia with Lewy bodies [9]. Active seizures, occurring within three years of the dementia diagnosis, were identified in nearly six percent of patients with Alzheimer's disease but only about three percent of those with dementia with Lewy bodies. In patients with Alzheimer's disease, seizure susceptibility was independently associated with advanced tau pathology, specifically Braak stage six, which nearly doubled the odds of seizures, and moderate-to-severe cerebral amyloid angiopathy, which increased the odds by about thirty-eight percent. In contrast, in patients with dementia with Lewy bodies, Alzheimer's-related pathology was not associated with seizures. Instead, vascular pathology was the dominant driver, with microinfarcts increasing the odds of seizures fivefold, and larger infarcts increasing the odds fourfold. This suggests that the biological mechanisms driving hyperexcitability and seizures are fundamentally different across these two common dementia subtypes, with tau and amyloid angiopathy driving seizures in Alzheimer's, and vascular lesions driving them in dementia with Lewy bodies.

Our final theme moves to acute brain injury, stroke, and clinical recovery. For patients with acute ischemic stroke due to large vessel occlusion, the time spent during interhospital transfer for endovascular therapy is a critical window. A study in Neurology investigated whether blood-brain barrier disruption, measured via perfusion magnetic resonance imaging at the primary stroke center before transfer, could predict clinical outcomes [5]. In a multicenter study of two hundred and eighty-nine patients, blood-brain barrier disruption was quantified as mean permeability derangement within the ischemic core. The researchers found that a mean permeability derangement of three percent or greater was independently associated with a more than sixfold increase in the risk of twenty-four-hour hemorrhagic transformation. Furthermore, this level of permeability derangement was associated with a threefold increase in the risk of a parenchymal hematoma and a threefold increase in the risk of a poor three-month functional outcome. These findings suggest that pre-transfer perfusion imaging can identify patients at high risk of hemorrhagic complications, potentially allowing clinicians to initiate targeted neuroprotective therapies during the transfer window before reperfusion occurs.

For patients recovering from ischemic stroke, a pooled individual participant-level data meta-analysis published in Stroke offers a promising therapeutic option to reduce long-term disability [7]. The analysis pooled data from two randomized, sham-controlled trials evaluating electromagnetic network-targeted field, or ENTF, brain stimulation. The therapy was initiated subacutely, between four and twenty-one days post-stroke, in one hundred and twenty-four patients with moderate-to-severe upper extremity motor impairment. At eight to twelve weeks, patients treated with active ENTF stimulation had a significantly higher rate of achieving freedom from disability, defined as a modified Rankin Scale score of zero or one, compared to those who received sham stimulation, with thirty-four percent versus twelve percent achieving this milestone. The active treatment group also demonstrated greater overall disability improvement and a shift toward lower final disability levels. Importantly, the device showed an excellent safety profile, with no device- or procedure-related serious adverse events reported, supporting its potential as a safe and effective non-invasive therapy to promote stroke recovery.

Finally, addressing acute brain injury on the sports field, JAMA Neurology published international consensus recommendations for a new football-specific on-pitch concussion assessment protocol, known as FOCUS [2]. Recognizing that on-pitch assessment in football, or soccer, is highly challenging due to strict time constraints, an international steering committee of medical experts from all six football confederations developed a standardized, evidence-informed protocol. Using a two-round Delphi process, they established a final forty-five-item protocol categorized into eleven domains. These domains include player medical history, mechanism of injury, visible signs, level of consciousness, cervical spine assessment, symptoms, orientation, balance, proprioception, oculomotor function, and activity-based assessment. Each domain is structured for rapid on-pitch evaluation. While the feasibility and diagnostic accuracy of the FOCUS protocol require further real-world evaluation, its adoption has the potential to harmonize concussion management and significantly improve player safety globally.

If you only have time for one paper this week, make it the phase three OVERLORD-MS trial comparing rituximab and ocrelizumab in newly diagnosed relapsing multiple sclerosis, published in The New England Journal of Medicine [1]. This head-to-head trial provides high-quality, practice-changing evidence that rituximab is noninferior to ocrelizumab in suppressing radiologic disease activity, offering clinicians a highly effective and potentially more accessible treatment option, despite a slightly higher rate of non-serious infections.

Here are the key takeaways from this week in Neurology: First, rituximab is noninferior to ocrelizumab for MRI disease control in newly diagnosed relapsing multiple sclerosis, though clinicians should monitor for a higher rate of non-serious infections with rituximab. Second, B-cell depleting therapies are uniquely effective among disease-modifying therapies at reducing chronic lesion tissue expansion, which is a key driver of progressive multiple sclerosis pathology. Third, implementing semiautomated coregistration-fusion software to compare sequential brain MRIs can help identify missed radiologic disease activity in one in five patients previously deemed stable, predicting future clinical and radiological progression. Fourth, blood-based circular RNAs represent a highly sensitive and specific diagnostic biomarker for early Alzheimer's disease, outperforming plasma p-tau-217 and predicting progression to symptomatic disease. And finally, pre-transfer perfusion magnetic resonance imaging showing blood-brain barrier disruption can identify stroke patients at high risk of hemorrhagic transformation and poor functional outcomes prior to endovascular therapy.

That's your roundup for This Week in Neurology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.